CN104162097B - 一种用于治疗胆石症并发脂肪肝的中药制剂 - Google Patents
一种用于治疗胆石症并发脂肪肝的中药制剂 Download PDFInfo
- Publication number
- CN104162097B CN104162097B CN201410346722.2A CN201410346722A CN104162097B CN 104162097 B CN104162097 B CN 104162097B CN 201410346722 A CN201410346722 A CN 201410346722A CN 104162097 B CN104162097 B CN 104162097B
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- liver
- fatty liver
- cholelithiasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 47
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 47
- 201000001883 cholelithiasis Diseases 0.000 title claims abstract description 47
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 47
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 241000270666 Testudines Species 0.000 claims abstract description 23
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 21
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 21
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 21
- 235000013976 turmeric Nutrition 0.000 claims abstract description 21
- 235000016068 Berberis vulgaris Nutrition 0.000 claims abstract description 17
- 241000601164 Clematis orientalis Species 0.000 claims abstract description 17
- 241000287828 Gallus gallus Species 0.000 claims abstract description 14
- 210000004317 gizzard Anatomy 0.000 claims abstract description 14
- 239000012528 membrane Substances 0.000 claims abstract description 14
- 240000004980 Rheum officinale Species 0.000 claims abstract description 12
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 12
- 241001647745 Banksia Species 0.000 claims abstract description 11
- 241000522190 Desmodium Species 0.000 claims abstract description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 11
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 11
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 11
- 241000220317 Rosa Species 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims abstract description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 11
- 240000000724 Berberis vulgaris Species 0.000 claims abstract 5
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 3
- 239000002245 particle Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 239000000052 vinegar Substances 0.000 claims description 7
- 235000021419 vinegar Nutrition 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 235000020380 turnip juice Nutrition 0.000 claims description 6
- 210000000941 bile Anatomy 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 3
- 239000010420 shell particle Substances 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims 1
- 235000008397 ginger Nutrition 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 10
- 208000019423 liver disease Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 208000029162 bladder disease Diseases 0.000 abstract description 2
- 238000002651 drug therapy Methods 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 208000026533 urinary bladder disease Diseases 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 208000002193 Pain Diseases 0.000 description 22
- 238000000034 method Methods 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 238000002604 ultrasonography Methods 0.000 description 15
- 241001083847 Berberis Species 0.000 description 12
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 10
- 206010023126 Jaundice Diseases 0.000 description 9
- 210000000232 gallbladder Anatomy 0.000 description 9
- 241000736199 Paeonia Species 0.000 description 8
- 238000010876 biochemical test Methods 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 239000004575 stone Substances 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 108090000340 Transaminases Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000014898 transaminase activity proteins Human genes 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 208000004845 Cholecystolithiasis Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 208000001130 gallstones Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 208000012287 Prolapse Diseases 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 210000000013 bile duct Anatomy 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010056375 Bile duct obstruction Diseases 0.000 description 3
- 206010004637 Bile duct stone Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 208000000996 Mirizzi syndrome Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 244000202052 Poncirus trifoliata Species 0.000 description 3
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 208000003167 cholangitis Diseases 0.000 description 3
- 201000001352 cholecystitis Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 206010004659 Biliary cirrhosis Diseases 0.000 description 2
- 206010008617 Cholecystitis chronic Diseases 0.000 description 2
- 201000009331 Choledocholithiasis Diseases 0.000 description 2
- 101800004637 Communis Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 244000178320 Vaccaria pyramidata Species 0.000 description 2
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000003512 furunculosis Diseases 0.000 description 2
- 239000003676 hair preparation Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017649 Gallstone ileus Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010036205 Portal vein phlebitis Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 210000001096 cystic duct Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于肝胆病中药技术领域,为了解决现有用来治疗胆石症的药物并不能很好根治同时患有并发症的胆石症的问题,提供了一种用于治疗胆石症并发脂肪肝的中药制剂。由威灵仙、柴胡、三颗针、青皮、金钱草、赤芍、郁金、枳壳、鸡内金、木香、虎杖、黄芩、姜黄、大黄、白芍、鳖甲、炮山甲、炒王不留行按一定比例制备而成。本发明药物治疗具有并发症的肝胆病患者212例,疗效显著,无毒副作用,总有效率达到96.32%,治愈率达到61.32%。
Description
技术领域
本发明属于肝胆病中药技术领域,具体涉及一种用于治疗胆石症并发脂肪肝的中药制剂。
背景技术
胆石症是指胆囊内或肝内外胆管任何部位发生结石所引起的一系列病理损害性疾病。中医认为,胆石症属于祖国医学“胁疼或者黄疸的范畴。中医认为,胆为六腑之一,以通降下行为顺,如因郁怒忧思,饮食不洁引起的肝胆气滞,疏泄失常,通降失调,则产生不通则痛的症状。
胆石症会引起一系列的并发症,胆石症最严重的并发症是不同严重程度的急性胆囊炎,包括坏疽性、气肿性胆囊炎,胆囊周围脓肿和穿孔等。慢性结石性胆囊炎也是胆囊结石常见的并发症。除此之外,胆囊结石的并发症还有胰腺炎、肝脓肿、胆管炎、上行性肝炎、门静脉炎、Mirizzi综合征和胆囊癌等。除了慢性胆囊炎(几乎每个胆囊结石患者都合并有慢性胆囊炎)之外,大约20%的胆囊结石患者会发生并发症,并且随着年龄增长,发生并发症的发病率明显增加。
Mirizzi综合征和合流结石:Mirizzi综合征是胆石症的一个少见的并发症。它是胆石嵌顿于胆囊颈部或胆囊管压迫肝总管并引起肝总管狭窄的一组症状。嵌顿于三管合流部的胆石,称之为合流结石。
胆总管结石的常见并发症为不同程度的胆管炎和胆管的细菌感染。其次,为胆石性胰腺炎、肝脓肿、败血症、胆肠瘘及胆石性肠梗阻等。因胆石压迫招致胆总管黏膜溃疡,进而引起胆总管狭窄者罕见。在我国,时而可见因胆石压迫引起胆管黏膜溃疡、坏死及出血,而西方国家,胆总管结石患者罕见胆道出血。此外,胆总管结石引起长期反复发作胆管炎及黄疸者可进一步发展成胆汁性肝硬化。
专利号为01141341.7公开了一种治疗胆石症的药物,所述药物临床治疗胆石症的总有效率达到96.15%,其中治愈率达到57.37%。剩余的38.78%只是起到的一定效果,而且这部分病人复发胆石症及其并发症的概率很高。经分析后发现,胆石症分布状况,第一,单纯的胆结石,并发症很少,例如胆囊结石,肝内外胆管结石。第二,具有并发症的胆结石,并发症主要有,脂肪肝,脂肪性肝炎,瘀胆性肝炎,胆汁性肝硬化。而在该申请中,能够达到治愈效果的病人,多为胆结石症状比较单一,且症状明显的病人。而患有并发症的病人,治疗效果较差。在长期临床实践中,发现有肝脏疾病的胆石症复发率高。具有比较严重的并发症的患者,不敢应用上述药物治疗方法,极大限制了治疗胆石症群体的范围。因此,申请人经过多年临床研究和实践后,在原有配方的基础上,进行了进一步的改进。以提高治疗胆石症伴有并发症群体的范围。
发明内容
本发明为了解决现有用来治疗胆石症的药物并不能很好根治同时患有并发症的胆石症的问题,提供了一种用于治疗胆石症并发脂肪肝的中药制剂。
本发明由如下技术方案实现的:一种用于治疗胆石症并发脂肪肝的中药制剂,由下列重量份的原料制成:威灵仙15-25份、柴胡9-15份、三颗针8-15份、青皮8-12份、金钱草19-25份、赤芍10-15份、郁金13-20份、枳壳8-15份、鸡内金9-15份、木香8-12份、虎杖11-15份、黄芩10-15份、姜黄10-15份、大黄8-15份、白芍12-18份、鳖甲25-35份、炮山甲8-12份、炒王不留行8-12份。
优选配比为:威灵仙20份、柴胡10份、三颗针10份、青皮10份、金钱草20份、赤芍12份、郁金15份、枳壳10份、鸡内金10份、木香10份、虎杖12份、黄芩12份、姜黄12份、大黄10份、白芍15份、鳖甲30份、炮山甲10份、炒王不留行10份。
制备方法为:除鳖甲、炮山甲、炒炒王不留外其余药物按照专利号01141341.7的发明专利中的制备方法进行药物处理:威灵仙用白萝卜汁按威灵仙:白萝卜汁4:1的比例炮制而成,三颗针用苦瓜汁按三颗针:苦瓜汁5:1的比例炮制而成,鸡内金制成粒径3mm以下后,与同等重量的鲜猪胆汁拌合,再装入猪膀胱内阴干而成;鳖甲、炮山甲破碎制成粒径3mm以下的颗粒,先将与鳖甲同等重量的陈醋煮沸20分钟,再按比例放入鳖甲颗粒,搅拌后放入容器内密封24小时,再加入炮山甲颗粒,搅拌均匀后再放入容器中密封24小时,最后与炒王不留行混合搅拌均匀再密封24小时,最后结块,然后将结块打散,阴干后和其他药物混合即可,制成中药散剂。
本发明所述中药制剂中,威灵仙:性辛、咸,温;归膀胱经;祛风除湿,通络止痛。用于风湿痹痛,肢体麻木,筋脉拘挛,屈伸不利,骨哽咽喉。柴胡:性苦、微寒;归肝、胆经;和解表里,疏肝,升阳。用于感冒发热,寒热往来,胸胁胀痛,月经不调,子官脱垂,脱肛。三颗针:性苦、寒;归肝;胃;大肠经;清热;燥湿;泻火解毒。主湿热痢利;腹泻;黄疸;湿疹;疮疡;口疮;目赤;咽痛。青皮:性苦、辛,温;归肝、胆、胃经;疏肝破气,消积化滞。用于胸胁胀痛,疝气,乳核,乳痈,食积腹痛。金钱草:性甘、咸,微寒;归肝、胆、肾、膀胱经;清利湿热,通淋,消肿。用于热淋,沙淋,尿涩作痛,黄疸尿赤,痈肿疔疮,毒蛇咬伤;肝胆结石,尿路结石。赤芍:性苦,微寒;归肝经;清热凉血,散瘀止痛。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。郁金:性辛、苦,寒;归肝、心、肺经;行气化瘀,清心解郁,利胆退黄。用于经闭痛经,胸腹胀痛、刺痛,热病神昏,癫痫发狂,黄疸尿赤。枳壳性苦、辛、酸,温;归脾、胃经。理气宽中,行滞消胀。用于胸胁气滞,胀满疼痛,食积不化,痰饮内停;胃下垂,脱肛,子官脱垂。鸡内金:性甘,平;归脾、胃、小肠、膀胱经;健胃消食,涩精止遗。用于食积不消,呕吐泻痢,小儿疳积,遗尿,遗精。木香:性辛、苦,温;归脾、胃、大肠、三焦、胆经;行气止痛,健脾消食。用于胸脘胀痛,泻痢后重,食积不消,不思饮食。煨木香实肠止泻。用于泄泻腹痛。虎杖:性微苦,微寒;归肝、胆、肺经;祛风利湿,散瘀定痛,止咳化痰。用于关节痹痛,湿热黄疸,经闭,症瘕,水火烫伤,跌扑损伤,痈肿疮毒,咳嗽痰多。黄芩:性苦,寒;归肺、胆、脾、大肠、小肠经;清热燥湿,泻火解毒,止血,安胎。用于湿温、暑温胸闷呕恶,湿热痞满,泻痢,黄疸,肺热咳嗽,高热烦渴,血热吐衄,痈肿疮毒,胎动不安。姜黄:性辛、苦,温;归脾、肝经;破血行气,通经止痛。用于胸胁剌痛,闭经,癓瘕,风湿肩臂疼痛,跌扑肿痛。大黄:性味;苦,寒;归脾、胃、大肠、肝、心包经;泻热通肠,凉血解毒,逐瘀通经。用于实热便秘,积滞腹痛,泻痢不爽,湿热黄疸,血热吐衄,目赤,咽肿,肠痈腹痛,痈肿疔疮,瘀血经闭,跌打损伤,外治水火烫伤;上消化道出血。酒大黄善清上焦血分热毒。用于目赤咽肿,齿龈肿痛。熟大黄泻下力缓,泻火解毒。用于火毒疮疡。大黄炭凉血化瘀止血。用于血热有瘀出血症。白芍:性苦、酸,微寒;归肝、脾经;平肝止痛,养血调经,敛阴止汗。用于头痛眩晕,胁痛,腹痛,四肢挛痛,血虚萎黄,月经不调,自汗,盗汗。鳖甲:性咸,微寒;归肝、肾经;滋阴潜阳,软坚散结,退热除蒸。用于阴虚发热,劳热骨蒸,虚风内动,经闭,癓瘕,久疟疟母。炮山甲:性咸,微寒;归肝、胃经;通经下乳,消肿排脓,搜风通络。用于经闭癓瘕,乳汁不通,痈肿疮毒,关节痹痛,麻木拘挛。炒王不留行:性苦,平;归肝、胃经;活血通经,下乳消肿。用于乳汁不下,经闭,痛经,乳痈肿痛。
在专利号01141341.7的发明专利配方的基础上再加入制鳖甲、制炮山甲、制炒王不留行三味中药,用以达到在治疗胆石症的同时消除伴发的脂肪肝,起到异病同治的作用。其中鳖甲经用陈醋腌制72小时,其主要功能为补充脂肪肝患者需要的特殊营养成分,增强机体免疫力,修复肝细胞功能,避免引起星状细胞活化,防止肝纤维化、肝硬化。炮山甲经用陈醋浸润48小时,其主要功能为抑制肿瘤坏死因子,避免胰岛素抵抗,抑制甘油三脂合成与积聚,清除引起肝细胞氧化损伤的过氧化物和活性自由基,避免肝细胞受损并促进受损肝细胞恢复,回缩因受损体积增大的肝脏,预防肝癌。炒王不留行经用陈醋焖润24小时,其具有增加肝细胞合成载脂蛋白的能力,从而加速脂肪和甘油三脂的运出,排出脂肪和毒素,有效清除脂肪肝。以上三味药用陈醋经特殊炮制后能增强软坚散结,消除痞满之功效。用以回缩因患脂肪肝体积变大的肝脏,清除脂肪肝,预防肝纤维化、肝硬化,降低胆固醇等作用。因含有多种微量元素和氨基酸,所以能够从根本上给肝脏提供所需营养物质。让肝脏细胞功能恢复的同时清除脂肪肝,调整胆固醇的分泌和代谢,调节胆汁的分泌和排泄,从而溶解胆结石。
本发明药物共凑舒肝利胆、排石溶石、清除脂肪肝、降血脂、降转氨酶、降血糖、降尿素氮,排出体内毒素,清肝明目,提高人体免疫功能等功效,从而达到胆石症、脂肪肝异病同治的目标,提高治愈率,扩大治疗范围。
本发明所述中药用于临床的情况如下:治疗具有并发脂肪肝的胆石病患者212例,30-70岁,患者每日口服本发明实施例2药物,每天1付,分3次服用,早午晚饭前温服,每次200-300g。40天为一个疗程,每疗程结束后休息2-3周进行理化检查复查。对照为申请号:01141341.7所公开的治疗胆石症的药物,治疗具有并发脂肪肝的胆石病患者100例,服药方法与服用本发明所述药物的方法相同。
诊断标准
病史:有长期酗酒、肥胖、糖尿病、营养失调及中毒性肝损害,慢性肝炎、胆石症等病史。妊娠急性脂肪肝常在妊娠36-40周。症状:一般轻度脂肪肝没有很明显的症状,部分脂肪肝患者会伴有恶心、乏力、厌食、嗳气、倦怠等感觉。中度脂肪肝患者会伴有肝区胀痛、腹胀等。而重度脂肪肝患者除了会有上述症状外,还伴有高血脂、高血压、糖尿病等症状。体征:部分脂肪肝患者可触及肿大的肝脏,表面光滑、边缘圆钝,有轻度压痛。影像检查:B超,从图上看脂肪肝患者的肝区呈现雪花状,强弱不均,后方回声增强,俗称亮肝。从回声是否均匀,血管是否清晰等方面判断出脂肪肝的程度。CT对诊断脂肪肝的准确性高于B超,对脂肪肝有诊断,分型、量化及鉴别诊断的意义。尤其对局限性脂肪肝,能更清楚地与肝癌、肝血管瘤、肝脓肿等相鉴别。生化检查:相关生化指标的正常与否,对脂肪肝的确诊以及程度判断,并发症的了解至关重要。如甘油三酯、胆固醇、血浆蛋白、谷丙转氨酶、谷草转氨酶、尿酸、尿素氮、血糖等生化指标的值。
疗效标准
治愈:临床症状,症状体征消失,B超复查,结石阴影消失,肝脏回声均匀,肝胆均未见异常;实验室报告,血生化各项指标正常。显效:症状体征消失,B超复查,结石大部分排出,并发脂肪肝较前减轻,实验室报告,各项生化指标基本正常,还有少量指标略有异常。有效:症状体征减轻,B超复查,并发症略有减轻,胆道内仍有结石。实验室报告各项生化指标略有下降。无效:症状体征不变,B超复查并发症及结石基本较前无改变。实验室检查各项生化指标无变化。
治疗方法:患者每日煎服本发明实施例2药物一付,每付药煎煮两次,将二次煎液混和,分早午晚饭前温服,每付药取散剂200-300g。40天为一个疗程,每疗程结束后休息2-3周进行理化检查复查。对照为申请号:01141341.7所公开的治疗胆石症的药物,治疗胆石症并发脂肪肝患者100例,服药方法与服用本发明所述药物的方法相同。
治疗结果:本发明实施例2所述药物与对照相比,治疗结果见表1。
表1
组别 | 治疗组 | 对照组 |
人数 | 212 | 100 |
治愈(治愈率) | 130(61.32%) | 18(18%) |
显效(显效率) | 50(23.59%) | 40(40%) |
有效(有效率) | 24(11.32%) | 30(30%) |
无效(无效率) | 8(3.77%) | 12(12%) |
总有效率 | 96.23% | 88% |
典型病例
1.王某,女,50岁,因腹痛,呕吐,头昏,四肢无力,就诊于我院,经理化检查、B超提示:脂肪肝(中度)、胆囊结石(多发性),血生化检查,转氨酶增高,胆红素增高,血脂增高,血糖增高,尿素氮增高。经服用本药物排石、消脂治疗,10天后临床症状消失,患者精神转佳,继服本药物30天,经过一疗程治疗,排出块状结石92块,最大者1.4cm,休息20天后复查,B超提示:脂肪肝(轻度),胆囊结石较前减少。血生化报告:转氨酶正常,胆红素正常,血脂略有增高,血糖正常,肾功能正常。患者开始第二疗程治疗,药物及方法同前。经过第二疗程治疗后,又排出块状结石24块,经过理化检查,B超报告,胆囊内无结石阴影,脂肪肝消失,肝脏恢复正常,血生化报告,各项指标正常。
2.闫某,女,63岁,因腹痛,恶心,呕吐就诊于我院,经检查患者体质偏胖,腹部较膨隆,右上腹及剑突下压痛,并可触及圆滑的肝缘,B超报告,脂肪肝(重度),胆囊结石(充满型),胆总管轻度扩张,血生化报告,血脂增高,血糖偏高,转氨酶增高,胆红素增高。血常规报告,白细胞总数增加,尿常规报告,尿胆原、胆红素阳性。
经西药抗生素治疗5天,症状体征减轻,白细胞总数正常。即停用西药,改服本药物排石,消脂治疗。经服用本药物一疗程排出砂粒性结石20余克,休息20天后复查,B超报告脂肪肝(中度),胆囊内结石减少,血生化报告,血脂、血糖较前降低,转氨酶、胆红素正常。患者心情愉快、配合服用第二疗程,药物及方法同前。经过第二疗程治疗后,又排出结石30余克,休息20天后再次复查,B超提示,脂肪肝(轻度),胆囊内留有少量结石,血生化报告,血糖正常,血脂略有偏高,患者自觉精力较前充沛,配合服用第三疗程,药物略有减量,又服一疗程,经过第三个疗程治疗后,又排出结石10余克小块状结石3块,休息20天后再次复查,B超报告,脂肪肝消失,胆囊内无结石阴影,肝胆恢复正常。血生化报告,各项指标无异常。该患者经以上3个疗程治疗,共排出砂粒状结石60余克,小块状结石3块,重度脂肪肝消失,体重减轻,病告痊愈。
3.郑某,男,69岁,行胆囊摘除术8年,因自感身体极度疲劳,肝区隐痛,腹胀,时有恶心,就诊于我院。经理化检查,B超提示,脂肪肝(轻度),胆管再生结石。血生化报告:血脂增高,转氨酶增高,胆红素增高,尿素氮偏高。经用本药物治疗10天后,临床症状消失,患者异常高兴,心情愉快,继服本药物30天,共排出绿豆大小结石6块,米粒大小结石20余块,休息20天复查,B超报告,脂肪肝消失,胆管内无结石阴影,血生化报告,各项指标正常。随访一年身体健康,再无复发。
具体实施方式
以下结合实施例对本发明作进一步详细描述。
实施例1:一种用于治疗胆石症并发脂肪肝的中药制剂,其特征在于:由下列重量份的原料制成:威灵仙15g、柴胡15g、三颗针8g、青皮8g、金钱草25g、赤芍10g、郁金20g、枳壳8g、鸡内金9g、木香8g、虎杖13g、黄芩10g、姜黄15g、大黄8g、白芍16g、鳖甲25g、炮山甲8g、炒王不留行8g。
制备方法为:除鳖甲、炮山甲、炒炒王不留外其余药物按照专利号01141341.7的发明专利中的制备方法进行药物处理:威灵仙用白萝卜汁按威灵仙:白萝卜汁4:1的比例炮制而成,三颗针用苦瓜汁按三颗针:苦瓜汁5:1的比例炮制而成,鸡内金制成粒径3mm以下后,与同等重量的鲜猪胆汁拌合,再装入猪膀胱内阴干而成;鳖甲、炮山甲破碎制成粒径3mm以下的颗粒,先将与鳖甲同等重量的陈醋煮沸20分钟,再按比例放入鳖甲颗粒,搅拌后放入容器内密封24小时,再加入炮山甲颗粒,搅拌均匀后再放入容器中密封24小时,最后与炒王不留行混合搅拌均匀再密封24小时,最后结块,然后将结块打散,阴干后和其他药物混合即可,制成中药散剂。
本实施例所制药物,同样采用上述的诊断依据、疗效标准以及治疗方法进行临床试验,对44名胆石症并发脂肪肝患者进行治疗,治疗结果:治愈者26例占59.10%,显效者11例占25%,有效者5例占11.36%;无效者2例占4.54%,总有效率达95.46%。
实施例2:一种用于治疗胆石症并发脂肪肝的中药制剂,其特征在于:由下列重量份的原料制成:威灵仙20份、柴胡10份、三颗针10份、青皮10份、金钱草20份、赤芍12份、郁金15份、枳壳10份、鸡内金10份、木香10份、虎杖12份、黄芩12份、姜黄12份、大黄10份、白芍15份、鳖甲30份、炮山甲10份、炒王不留行10份。制备方法同实施例所述制备方法。
实施例3:一种用于治疗胆石症并发脂肪肝的中药制剂,其特征在于:由下列重量份的原料制成:威灵仙25g、柴胡9g、三颗针15g、青皮12g、金钱草19g、赤芍15g、郁金13g、枳壳15g、鸡内金15g、木香12g、虎杖11g、黄芩15g、姜黄10g、大黄15g、白芍12g、鳖甲35g、炮山甲12g、炒王不留行12g。制备方法同实施例所述制备方法。本实施例所制药物,同样采用上述的诊断依据、疗效标准以及治疗方法进行临床试验,对50名胆石症并发脂肪肝患者进行治疗,治疗结果:治愈者30例占60%,显效者12例占24%,有效者6例占12%;无效者2例占4%,总有效率达96%。
实施例4:一种用于治疗胆石症并发脂肪肝的中药制剂,其特征在于:由下列重量份的原料制成:威灵仙18g、柴胡12g、三颗针12g、青皮9g、金钱草19g、赤芍14g、郁金20g、枳壳8g、鸡内金12g、木香9g、虎杖15g、黄芩14g、姜黄13g、大黄13g、白芍18g、鳖甲32g、炮山甲11g、炒王不留行11g。制备方法同实施例所述制备方法。本实施例所制药物,同样采用上述的诊断依据、疗效标准以及治疗方法进行临床试验,对40名胆石症并发脂肪肝患者进行治疗,治疗结果:治愈者23例占57.5%,显效者11例占27.5%,有效者4例占10%;无效者2例占5%,总有效率达95%。
实施例5:一种用于治疗胆石症并发脂肪肝的中药制剂,其特征在于:由下列重量份的原料制成:威灵仙15g、柴胡13g、三颗针15g、青皮11g、金钱草22g、赤芍10g、郁金16g、枳壳15g、鸡内金9g、木香12g、虎杖14g、黄芩11g、姜黄15g、大黄8g、白芍12g、鳖甲35g、炮山甲12g、炒王不留行8g。制备方法同实施例所述制备方法。本实施例所制药物,同样采用上述的诊断依据、疗效标准以及治疗方法进行临床试验,对48名胆石症并发脂肪肝患者进行治疗,治疗结果:治愈者29例占60.42%,显效者12例占25%,有效者5例占10.41%;无效者2例占4.17%,总有效率达95.83%。
Claims (3)
1.一种用于治疗胆石症并发脂肪肝的中药制剂,其特征在于:由下列重量份的原料制成:威灵仙15-25份、柴胡9-15份、三颗针8-15份、青皮8-12份、金钱草19-25份、赤芍10-15份、郁金13-20份、枳壳8-15份、鸡内金9-15份、木香8-12份、虎杖11-15份、黄芩10-15份、姜黄10-15份、大黄8-15份、白芍12-18份、鳖甲25-35份、炮山甲8-12份、炒王不留行8-12份。
2.根据权利要求1所述的一种用于治疗胆石症并发脂肪肝的中药制剂,其特征在于:由下列重量份的原料制成:威灵仙20份、柴胡10份、三颗针10份、青皮10份、金钱草20份、赤芍12份、郁金15份、枳壳10份、鸡内金10份、木香10份、虎杖12份、黄芩12份、姜黄12份、大黄10份、白芍15份、鳖甲30份、炮山甲10份、炒王不留行10份。
3.根据权利要求1或2所述的一种用于治疗胆石症并发脂肪肝的中药制剂,其特征在于:制备方法为:威灵仙用白萝卜汁按威灵仙:白萝卜汁4:1的比例炮制而成,三颗针用苦瓜汁按三颗针:苦瓜汁5:1的比例炮制而成,鸡内金制成粒径3mm以下后,与同等重量的鲜猪胆汁拌合,再装入猪膀胱内阴干而成;鳖甲、炮山甲破碎制成粒径3mm以下的颗粒,先将与鳖甲同等重量的陈醋煮沸20分钟,再按比例放入鳖甲颗粒,搅拌后放入容器内密封24小时,再加入炮山甲颗粒,搅拌均匀后再放入容器中密封24小时,最后与炒王不留行混合搅拌均匀再密封24小时,最后结块,然后将结块打散,阴干后和其他药物混合制成中药散剂即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410346722.2A CN104162097B (zh) | 2014-07-21 | 2014-07-21 | 一种用于治疗胆石症并发脂肪肝的中药制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410346722.2A CN104162097B (zh) | 2014-07-21 | 2014-07-21 | 一种用于治疗胆石症并发脂肪肝的中药制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104162097A CN104162097A (zh) | 2014-11-26 |
CN104162097B true CN104162097B (zh) | 2018-01-09 |
Family
ID=51906222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410346722.2A Expired - Fee Related CN104162097B (zh) | 2014-07-21 | 2014-07-21 | 一种用于治疗胆石症并发脂肪肝的中药制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104162097B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104906269A (zh) * | 2015-06-28 | 2015-09-16 | 徐国华 | 一种用于治疗胆结石的口服液 |
CN114392339A (zh) * | 2022-01-24 | 2022-04-26 | 国鼎山河(海南)医药集团有限责任公司 | 一种用于胆囊炎胆结石息肉的组合物及其用途与制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1378854A (zh) * | 2001-10-14 | 2002-11-13 | 温补来 | 治疗胆石症的药物及配制方法 |
-
2014
- 2014-07-21 CN CN201410346722.2A patent/CN104162097B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1378854A (zh) * | 2001-10-14 | 2002-11-13 | 温补来 | 治疗胆石症的药物及配制方法 |
Non-Patent Citations (1)
Title |
---|
中药治疗胆石症药理机制;薛筠;《医学综述》;20090605;第5卷(第11期);1709-1712 * |
Also Published As
Publication number | Publication date |
---|---|
CN104162097A (zh) | 2014-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103734548B (zh) | 用于治疗猪消化不良的饲料及其制备方法 | |
CN102671050A (zh) | 一种治疗肺脓肿的中药制剂 | |
CN105166545A (zh) | 一种牛配合饲料及其制备方法 | |
CN105106754A (zh) | 一种食疗抗癌制剂及其制备方法 | |
CN104940784B (zh) | 一种治疗慢性胃炎的中药组合物 | |
CN104162097B (zh) | 一种用于治疗胆石症并发脂肪肝的中药制剂 | |
CN103989955A (zh) | 一种治疗胃、十二指肠溃疡、浅表性多发性胃溃疡、糜烂性胃溃疡的药物组合物 | |
CN103316175B (zh) | 一种中药散剂及其制备方法和应用 | |
CN104758606A (zh) | 一种治疗气虚痰瘀型肝血管瘤的中药组合物 | |
CN103877457B (zh) | 一种治疗肾结石的中药制剂及制备方法 | |
CN102580032B (zh) | 具有促排石作用的中药组合物片剂、散剂、口服液及制备方法 | |
CN103212026B (zh) | 一种治疗胆石症的中药及其制备方法和服用方法 | |
CN100418572C (zh) | 一种治疗肝胆病的口服中药制剂 | |
CN103735906A (zh) | 一种治疗干性支气管扩张的中药制剂及其制备方法 | |
CN109893622A (zh) | 一种新生儿黄疸的中药外洗方 | |
CN108653685A (zh) | 一种治疗肝硬化的中药组合物及其制备方法 | |
CN105288274A (zh) | 医治肾病综合征的利尿消肿制剂及制备方法 | |
CN106237245B (zh) | 一种治疗急慢性腹泻的中药组合物及其制剂和应用 | |
CN104887841A (zh) | 治疗痛风的中药制剂 | |
CN106267077B (zh) | 一种治疗肠系膜淋巴结炎的中药组合物及其制剂和应用 | |
CN105288344A (zh) | 一种用于治疗肝胆结石的中药组合物及其应用 | |
CN103751675B (zh) | 用于治疗猪消化不良的药物及其制备方法 | |
CN104940837A (zh) | 一种治疗胆结石的中药 | |
CN105079771A (zh) | 一种治疗术后肠粘连性肠梗阻的中药组合物 | |
CN113855778A (zh) | 一种治疗脾肾阳衰顽痰痼血型食管癌的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180109 Termination date: 20200721 |